Original Article

Comparison of laboratory biomarkers for the prediction of in-hospital mortality and severity of acute pulmonary embolism

A multi-center study

Yasir M. Alsubhi, MD, Ahmed H. Alhadi, MD, Abdulaziz M. Hammudah, MD, Riyadh A. Alahmadi, MD, Azhar M. Aljohani, MD, Sami Al Dubai, DrPH, Abdulqader I. Susi, MD, Kholoud Almuwallad, MD, Turki A. Alwasaidi, MD.

ABSTRACT

الأهداف: معرفة خصوصية وحساسية هذه المؤشرات المخبرية الحيوية التنبؤية في مرضى الانسداد الرئوي الحاد (PE) .

المنهجية: تم تطبيق دراسة رصدية بأثر رجعي على 162 مريض من أصل 741 مريضًا تم إدخالهم إلى المستشفى بعد تشخيصهم بالانسداد الرئوي الحاد عن طريق التصوير المقطعي المحوسب للأوعية الدموية الرئوية. تم جمع البيانات من خمس مستشفيات بين يناير 2015م و ديسمبر. 2019م تم تقسيم المرضى الى مجموعتين ناجين و غير ناجين. تم تسجيل نسبة العدلات إلى الخلايا الليمفاوية، عرض توزيع الخلايا الحمراء و نسبة الصفائح الدموية إلى الخلايا الليمفاوية و مقارنتها بين المجموعتين. تم استخدام المنحني المميز لأداء المستقبل (ROC) لتقييم خصوصية وحساسية التحاليل المخبرية في التنبؤ بمعدل الوفاة.

النتائج : ارتبط كل من نسبة العدلات إلى الحلايا الليمفاوية وعرض توزيع الحلايا الحمراء بشكل كبير مع ارتفاع معدل الوفيات و شدة المرض. من أصل 162 مريض، توفي 8 مرضى. عند نقطة الانقطاع 5.5، ارتبطت نسبة العدلات إلى الخلايا الليمفاوية بجميع أسباب الوفاة بحساسية %75 وخصوصية %88. عند نقطة الانقطاع 18.15، ارتبط عرض توزيع الخلايا الحمراء بجميع أسباب الوفاة بحساسية %63 وخصوصية %88.

الخلاصة : عوامل متعددة لها دور في معدل وفيات وشدة مرض الانسداد الرئوي الحاد . حددت دراستنا ارتباطًا مهمًا بين معدل الوفيات ونسبة العدلات إلى الخلايا الليمفاوية وعرض توزيع الخلايا الحمراء . يمكن الوصول الى هذه العوامل المخبرية بسهولة وقد توفر أيضا نظرة اولية تنبؤية لمعدل الوفيات في مرضى الانسداد الرئوي الحاد .

Objectives: To assess the specificity and sensitivity of prognostic biomarkers in individuals diagnosed with acute pulmonary embolism (PE).

Methods: This study retrospectively enrolled 162 patients from the 741 patients who were hospitalized with acute PE and diagnosed using pulmonary computed tomography (CT) angiogram at 5 hospitals in Saudi Arabia between January 2015 and December 2019. Pulmonary embolism patients classified into survivor and non-survivor groups. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and red cell distribution width (RDW) were all recorded and were compared between the groups. The evaluation of mortality prediction, sensitivity, and specificity was carried out by employing receiver operating characteristic curves. **Results:** The variables NLR and RDW exhibited a statistically significant correlation with increased mortality and disease severity. A total of 8 patients among the 162 patients died. At the cut-off value of 5.5, NLR was showed an association with all-cause mortality, demonstrating a sensitivity of 75% and a specificity of 82%. At the cut-off value of 18.15, RDW was found to be significantly associated with all-cause mortality, displaying a sensitivity of 63% and a specificity of 88%.

Conclusion: Multiple parameters have been implicated in the mortality and severity of PE. Our study revealed a statistically significant association between NLR, RDW, and PE mortality. These tests are easily accessible and may provide insights into the mortality associated with PE.

Keywords: biomarkers, platelet-to-lymphocyte ratio, red cell distribution width, neutrophil-to-lymphocyte ratio, pulmonary embolism

Saudi Med J 2023; Vol. 44 (9): 898-903 doi: 10.15537/smj.2023.44.9.20230441

From the Department of Medicine (Alsubhi, Hammudah, Alahmadi); from the Department of Critical Care (Almuwallad), King Fahad General Hospital, from the Department of Medicine (Alhadi); from the Division of Hematology (Alwasaidi), Prince Mohammed Bin Abdulaziz Hospital, Ministry of National Guard Health Affairs, from the Department of Preventive Medicine (Aljohani), Division of Infection Prevention and Control; from the Preventive Medicine Joint Program (Al Dubai), Post Graduate Studies, Ministry of Health, from the Department of Medicine (Alwasaidi), College of Medicine, Taibah University, Al-Madinah Al-Munawarah, and from the Department of Emergency Medicine (Susi), King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.

Received 12th June 2023. Accepted 14th August 2023.

Address correspondence and reprint request to: Dr. Yasir M. Alsubhi, Department of Medicine, King Fahad General Hospital, Ministry of Health, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia. E-mail: yasiralsubhimd@gmail.com ORCID ID: https://orcid.org/0009-0005-5084-8653



Dulmonary embolism (PE) ranks as the third most **L** prevalent cause of cardiovascular mortality in hospitalized individuals within Western nations.¹ The main mechanism underlying the development of PE is the detachment of the vein thrombus, usually from the lower limb, and its passage to the lung arteries.² Most clinical presentations of PE are non-specific, resulting in frequent misdiagnosis.³ Pulmonary embolism is associated with significant morbidity; thus, it requires accurate evaluation and diagnosis. Pulmonary angiography is the most accurate method for diagnosing PE; however, it is not used frequently in clinical practice due to its high cost and invasive nature. Computed tomography (CT) pulmonary angiogram and ventilation-perfusion scans are frequently employed diagnostic procedures that are considered to be less invasive in nature.⁴ Anticoagulant therapy is the mainstay of treatment for PE; however, massive PEs may require thrombolytic therapy.⁵ Previous studies have demonstrated the validity and utility of the existing prognostic models for acute PE. Although all of these models predict the mortality rate and risk stratification, they also have some differences. For instance, the American Heart Association (AHA) and European Society of Cardiology (ESC) prognostic models are used to identify patients who require therapeutic thrombolysis.^{6,7} In contrast, the simplified pulmonary embolism severity index (sPESI) is used for the purpose of identifying individuals with a low risk of PE, therefore determining their suitability for outpatient treatment.⁸ Neutrophil-to-lymphocyte ratio (NLR), red cell distribution width (RDW), and plateletto-lymphocyte ratio (PLR) are emerging prognostic laboratory biomarkers for several acute conditions, such as pneumonia and multiple chronic diseases including, cancers.9,10

The objective of this study was to assess the specificity and sensitivity of laboratory biomarkers in predicting in-hospital mortality and disease severity among patients diagnosed with acute PE. These biomarkers reflect the role of the inflammatory factors in the coagulation cascade. The pathophysiology of thrombus formation involves an interaction between the inflammatory and coagulation pathways.¹¹

Methods. This retrospective cohort study examined a sample of 162 patients out of a total of 741 individuals who were diagnosed with PE at 5 hospitals (King Fahad

Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

General Hospital, Al-Madinah Al-Munawarah, King Fahad Medical City, Riyadh, and the National Guard Hospitals in Al-Madinah Al-Munawarah, Jeddah, and Riyadh, Saudi Arabia) from January 2015 to December 2019. Electronic registries of the King Fahad General Hospital, Al-Madinah Al-Munawarah, King Fahad Medical City, Riyadh, and the National Guard Hospitals in Al-Madinah Al-Munawarah, Jeddah, and Riyadh, Saudi Arabia, were used for this purpose.

The data were filtered based on the inclusion and exclusion criteria (Table 1). In total, 162 patients who satisfied the predefined inclusion criteria were enrolled in the present study.

Electronic hospital information systems were used to obtain the clinical, demographic data, and laboratory parameters results. Clinical vital signs (pulse rate, blood pressure [BP], and oxygen saturation) and laboratory results were used to classify the PEs as low-risk, submassive, or massive. Low-risk PE was defined as the absence of the criteria for massive or sub-massive PEs based on AHA risk stratification. Sub-massive PE was defined as the presence of normal blood pressure (systolic BP [SBP] of >90 mmHg) with signs of right ventricular dysfunction or increased levels of troponin. Massive PE was defined as the presence of continuous hypotension (SBP of <90 mmHg) for more than 15 minutes or the use of inotropes for maintaining the BP within normal limits. The NLR, RDW, and PLR data were obtained from the laboratory results at the time of arrival at the emergency department. Neutrophil-to-lymphocyte ratio represents the proportion of neutrophils to lymphocytes, while PLR denotes the ratio of platelets to lymphocytes.

The present study obtained approval from the Institutional Review Board of the Ministry of Health

Inclusion criteria	Exclusion criteria			
Age 18 years or older	Sepsis (based on the results of the blood cultures)			
Diagnosis by CTPA	Chronic inflammatory diseases			
Availability of all required data	Malignancy			
	Active use of immunosuppressive			
	Previous PE history			
	End-stage renal disease			
	Pregnancy			
	COVID-19			
	History of hematological diseases			
CTPA: computed tomography pulmonary angiogram, PE: pulmonary embolism, COVID-19: coronavirus disease-19				

Table 1 - The inclusion and exclusion criteria.

and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (IRB: 1173/22).

Statistical analysis. The Statistical Package for the Social Sciences, version 22 (IBM Corp., Armonk, NY, USA), was utilized in the analysis. Descriptive statistics were applied to calculate the frequencies (n) and percentages (%) pertaining to all categorical variables, whereas means and standard deviations (SDs) were used to describe the scale variables. The normality of the scale variables was assessed using the Shapiro-Wilk and Kolmogorov-Smirnov tests. The associations between mortality and the categorical variables were assessed using the Chi-square test, whereas the t-test was used to evaluate the associations between mortality and the continuous variables. Receiver operating characteristic (ROC) curves were obtained for NLR and RDW to illustrate their overall ability to predict mortality, sensitivity, and specificity. Youden's J statistic was calculated to determine the best cut-off values for NLR and RDW. A p-value of <0.05 was considered significant.

Results. The analysis included 162 participants who met the inclusion and exclusion criteria. A total of 8 (5%) patients experienced mortality during the designated study period. The mean age of all participants was 60.6 ± 18.9 years, with the ages ranging from 21-94 years.

Tables 2 & 3 present the sociodemographic and clinical characteristics of the participants. Patients with acute PE who subsequently died exhibited a statistically significant decrease in lymphocyte $(1.17\pm0.45 \text{ vs.} 2.0\pm0.85; p=0.007)$ and platelet counts $(154\pm112 \text{ vs.} 281\pm117; p=0.003)$.

Red cell distribution width was significantly higher in the patients who died $(17.82\pm3.54 \text{ vs. } 14.97\pm3.02;$ p=0.011, Figure 1). The patients who died demonstrated a significantly higher NLR (10.5±6.2 vs. 3.9±3.0; p < 0.001, Figure 2) as well. High-risk patients based on the sPESI had significantly higher mortality rate (9.9%) compared to those who low risk (0.0%; p=0.004). The mortality rate was found to be significantly associated with the location of PE, with the saddle location of the PE exhibiting the highest mortality rate (p < 0.001). Patients diagnosed with massive PE shown a considerably elevated mortality rate compared to individuals diagnosed with sub-massive or low-risk PEs (p=0.001). The majority of patients (58.6%) had low-risk PE, whereas 36.4% had sub-massive PE and 5% had massive PE.

Table 3 presents the association between PE severityand NLR, PLR, and RDW. Neutrophil-to-lymphocyte

ratio was significantly higher in patients with massive PEs (10.6±6.1) than that in those with sub-massive (4.7±3.8) or low-risk PE (3.4±2.3; p<0.001). Similarly, RDW was significantly higher in patients with massive PEs (17.55±3.50) than that in those with sub-massive (15±2.8) or low-risk PEs (14.97±3.18; p<0.05).

There was an absence of statistically significant variation in PLR between patients with low-risk, submassive, and massive PEs (p>0.05). The area under the curve (AUC) for NLR based on the ROC curve analysis was 0.87 (95% confidence interval [CI]: [0.77-0.97]; p<0.001) and for RDW it was 0.75 (95% CI: [0.55-0.94]; p<0.019). At the cut-off value of 5.5, NLR had a sensitivity of 75% and specificity of 82%. At the cut-off value of 18.15, RDW had a sensitivity of 63% and specificity of 88% (Figure 3).

Discussion. In recent years, NLR, RDW, and PLR have been used to predict the prognosis of multiple disorders, such as sepsis and acute heart failure, at the emergency level of care and for the assessment of mood disorders.¹²⁻¹⁴ Moreover, these factors have wide acceptance due to their availability and low cost. The usefulness of these markers may be attributed to their ability to indicate the severity of the inflammatory process due to underlying diseases.¹³

Red cell distribution width is a numerical value that describes in percentage the differentiation in the red blood cell size, and its normal value ranges from 12-15%.¹⁵ Neutrophil-to-lymphocyte ratio is the ratio between the neutrophil and lymphocyte counts, and its normal value ranges from 0.78-3.53.16 Platelet-tolymphocyte ratio is the ratio between the platelet and lymphocyte counts, and a higher value of PLR is linked to increased inflammation.¹⁷ The findings of our study indicate a statistically significant association between elevated NLR and in-hospital mortality, as observed in the analysis of the 162 patients included in the study (Figure 2). Patients diagnosed with massive PE showed a notably elevated mortality rate compared to individuals diagnosed with sub-massive or low-risk PEs (p=0.001). Furthermore, it was observed that a higher NLR was correlated with increased severity of PE according to the AHA risk stratification for acute PE (Table 3). This finding supports the findings of multiple clinical studies showing that NLR is an inexpensive, fast, sensitive, specific, valuable, routinely ordered, and simple to calculate test that can be used for risk stratification and mortality prediction in patients with acute PE.^{18,19} The cut-off value for NLR in our study was 5.5, with a sensitivity of 75% and specificity of 82% for predicting

Variables	Non-survivors (n=8)	Survivors (n=154)	P-values
Age (years)	64±22	60±19	0.576
Weight (kg)	71.3±23.3	86.9±28.1	0.124
Height (cm)	164±9	157±23	0.331
Neutrophil count, absolute (10 ⁹ /L)	11.45±6.12	6.73±6.62	0.050
Lymphocyte count, absolute (10 ⁹ /L)	1.17±0.45	2.0±0.85	0.007
NLR	10.5±6.2	3.9±3.0	< 0.001
Platelets (10 ⁹ /L)	154±112	281±117	0.003
PLR	141.0±73.23	166.9±101.7	0.479
HGB (g/dL)	10.7±2.5	13.2±7.0	0.317
RDW (%)	17.82±3.54	14.97±3.02	0.011
Troponin I level (ng\ml)	1.35±1.98	0.46±1.34	0.076
D-dimer (µg/mL)	6.07±2.97	9.70±0.32	0.727
Gender			
Female	4 (4.5)	84 (95.5)	0.901
Male	4 (5.4)	70 (94.6)	0.801
PE location (by CT angio)			
Lobar	0 (0.0)	69 (100)	
Saddle	8 (25.8)	23 (74.2)	< 0.001
Segmental	0(0.0)	56 (100)	
Subsegmental (SSPE)	0 (0.0)	6 (100)	
sPESI	0 (0 0)	72 (00.1)	
High	8 (9.9)	/3 (90.1) 81 (100)	0.004
Chronic diseases	0 (0.0)	01 (100)	
Vac	1(3/4)	28 (96 6)	
No	7 (5.3)	126 (94.7)	0.683
Pulmonary embolism severity	, (3.3)	120 () 11/)	
Low risk	0(0,0)	95 (100)	
Sub-massive	1 (1.7)	58 (98.3)	0.001
Massive	7 (87.5)	1 (12.5)	
Massive	7 (87.5)	1 (12.5)	(0D)

Table 2 - The soci	odemographic and	clinical cl	haracteristics	of the	participants	(N=162	2).
--------------------	------------------	-------------	----------------	--------	--------------	--------	-----

Values are presented as numbers and precentages (%) or mean ± standard deviation (SD). NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, RDW: red cell distribution width, CT angio: computed tomography angiography, HGB: hemoglobin, SSPE: subsegmental pulmonary embolism, PE: pulmonary embolism, sPESI: simplified pulmonary embolism severity index

 Table 3 - Distribution of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width according to the severity of pulmonary embolism.

Parameters	Low risk PE (n=95)	Sub-massive PE (n=59)	Massive PE (n=8)	P-values		
NLR	3.4±2.3	4.7±3.8	10.6±6.1	< 0.001		
PLR	174.94±99.70	153.83±104.24	143.03±75.65	0.365		
RDW	14.97±3.18	15.00±2.80	17.55±3.50	0.042		
Values are presented as mean ± standard deviation (SD). NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, RDW: red cell distribution width, PE: pulmonary embolism						

all-cause mortality. Other studies have reported similar cut-off ranges, sensitivities, and specificities.^{18,19}

The existing comprehension of the correlation between of a higher NLR and mortality is based on the involvement of inflammation in the development of thrombosis.²⁰ During acute stress, the secretion of corticosteroids and adrenaline increases, thereby decreasing the lymphocyte count and increasing the leukocyte count.²¹ The more acute and stressful the condition, the higher the NLR is.

The second most significant prognostic factor was RDW. In our study, a significant relationship was



Figure 1 - Comparison of red cell distribution width (RDW) in patients with acute pulmonary embolism based on the survival and mortality.



Figure 2 - Comparison of neutrophil-to-lymphocyte ratio (NLR) in patients with acute pulmonary embolism based on the survival and mortality.

observed between RDW, PE severity, and mortality, similar to NRL. Evidence from our study showed that RDW was significantly higher among patients who died (17.82±3.54 vs. 14.97±3.02; p=0.011, Figure 1). The cut-off value in our study was 18.15, with a sensitivity of 63% and specificity of 88%. A study carried out revealed a significant correlation between RDW and mortality occurring during a patient's hospital stay with a cut-off value of ≥15 and sensitivity of 66% and specificity of 59% for all-cause deaths.²²

A previous study reported that patients with massive PEs had significantly higher RDW than those with non-massive PEs, the optimal cut-off value for RDW that had the highest combined sensitivity and specificity was >14 (sensitivity of 72% and specificity of 46%).²³ In our study, RDW was higher in patients with massive PE (17.55±3.50) than that in those with sub-massive (15.00±2.80), or low-risk PEs (14.97±3.18, p=0.042).

Severe hypoxia in acute events, such as pneumonia, will induce the bone marrow to produce new large red



Figure 3 - Receiver operating characteristic curve illustrating the area under the curve sensitivity and specificity of neutrophil to lymphocyte ratio (NLR) and red cell distribution width (RDW) for predicting mortality.

blood cells under the effect of erythropoietin secretion secondary to hypoxia and stress.²⁴ Platelet-to-lymphocyte ratio can be a useful biomarker for predicting acute PE as it is a part of the systemic inflammatory response (SIR).²⁵ However, the findings of our study showed no significant value of PLR as an indicator of PE severity or mortality (p>0.05). In contrast, another study reported that PLR had a significant prognostic value at a cut-off value of 191 and was associated with high 30-day mortality, with a sensitivity of 60.6% and specificity of 83.2% (p=0.01).¹⁹ Low platelet counts were observed in the massive PE group. These patients did not receive anticoagulants or thrombolytic therapy, and their platelet levels were measured at the emergency department level. A previous study showed that the platelet count in massive PE group is lower than submassive and low-risk PE groups.²⁶ In addition, a meta-analysis of platelet indices for the risk stratification of acute PE reported that patients with acute PE had higher mean platelet volume and lower platelet counts.²⁷

To clarify this point, the baseline of the patients must be recorded before the development of PE in further prospective studies. Lastly, based on our cut-off value for predicting all-cause mortality for both NLR (5.5) and RDW (18.15), we suggest using NLR and RDW in establishing a management plan for submassive PE in future prospective studies. This incorporation may help in making decisions regarding thrombolysis therapy for this group. As well as incorporation with other PE risk stratification models may facilitate the choice of treatment disposition.

Study limitations. This study had a small sample size. Moreover, the retrospective design of the study was a limitation. Another limitation of our study was that

NLR and PLT had no universal reference for the normal range based on age, gender, and ethnicity. Further studies are required to identify the normal ranges of NRL and PLR in different populations.

In conclusion, NLR and RDW are simple and inexpensive tests that can be carried out at the emergency department level and may indicate prognostic value. Their role as prognostic factors can be explained by their relationship with the severity of inflammation. These factors are independent predictors of mortality and disease severity in patients with acute PE.

Acknowledgment. The authors gratefully acknowledge Editage for their English language editing.

References

- Keeling WB, Leshnower BG, Lasajanak Y, Binongo J, Guyton RA, Halkos ME, et al. Midterm benefits of surgical pulmonary embolectomy for acute pulmonary embolus on right ventricular function. *J Thorac Cardiovasc Surg* 2016; 152: 872-878.
- Turetz M, Sideris AT, Friedman OA, Triphathi N, Horowitz JM. Epidemiology, pathophysiology, and natural history of pulmonary embolism. *Semin Intervent Radiol* 2018; 35: 92-98.
- Toplis E, Mortimore G. The diagnosis and management of pulmonary embolism. *Br J Nurs* 2020; 29: 22-26.
- Moore AJE, Wachsmann J, Chamarthy MR, Panjikaran L, Tanabe Y, Rajiah P. Imaging of acute pulmonary embolism: an update. *Cardiovasc Diagn Ther* 2018; 8: 225-243.
- Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of pulmonary embolism: an update. *J Am Coll Cardiol* 2016; 67: 976-990.
- Elias A, Mallett S, Daoud-Elias M, Poggi JN, Clarke M. Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis. *BMJ Open* 2016; 6: e010324.
- Jara-Palomares L, Alfonso M, Maestre A, Jimenez D, Garcia-Bragado F, Font C, et al. Comparison of 7 prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. *Sci Rep* 2019; 9: 20064.
- Giri J, Sista AK, Weinberg I, Kearon C, Kumbhani DJ, Desai ND, et al. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. *Circulation* 2019; 140: e774-e801.
- Qi X, Dong Y, Lin X, Xin W. Value of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and red blood cell distribution width in evaluating the prognosis of children with severe pneumonia. *Evid Based Complement Alternat Med* 2021; 2021: 1818469.
- Chen W, Xin S, Xu B. Value research of NLR, PLR, and RDW in prognostic assessment of patients with colorectal cancer. J Healthc Eng 2022; 2022: 7971415.
- Wang Q, Ma J, Jiang Z, Ming L. Prognostic value of neutrophilto-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. *Int Angiol* 2018; 37: 4-11.

- Chen CK, Lin SC, Wu CC, Chen LM, Tzeng IS, Chen KF. STARD-compliant article: the utility of red cell distribution width to predict mortality for septic patients visiting the emergency department. *Medicine (Baltimore)* 2016; 95: e3692.
- Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. *Arq Bras Cardiol* 2015; 105: 606-613.
- Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and platelet/ lymphocyte ratio in mood disorders: a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* 2018; 84: 229-236.
- Lippi G, Plebani M. Red blood cell distribution width (RDW) and human pathology. One size fits all. *Clin Chem Lab Med* 2014; 52: 1247-1249.
- Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-tolymphocyte ratio? *BMC Res Notes* 2017; 10: 12.
- Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. *Ann Lab Med* 2019; 39: 345-357.
- Phan T, Brailovsky Y, Fareed J, Hoppensteadt D, Iqbal O, Darki A. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict all-cause mortality in acute pulmonary embolism. *Clin Appl Thromb Hemost* 2020; 26: 1076029619900549.
- Karataş MB, İpek G, Onuk T, Güngör B, Durmuş G, Çanga Y, et al. Assessment of prognostic value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with pulmonary embolism. *Acta Cardiol Sin* 2016; 32: 313-320.
- 20. Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. *Thromb Res* 2018; 170: 87-96.
- Ince LM, Weber J, Scheiermann C. Control of leukocyte trafficking by stress-associated hormones. *Front Immunol* 2019; 9: 3143.
- Ozsu S, Abul Y, Gunaydin S, Orem A, Ozlu T. Prognostic value of red cell distribution width in patients with pulmonary embolism. *Clin Appl Thromb Hemost* 2014; 20: 365-370.
- Omar HR, Mirsaeidi M, Rashad R, Hassaballa H, Enten G, Helal E, et al. Association of serum albumin and severity of pulmonary embolism. *Medicina (Kaunas)* 2020; 56: 26.
- Yčas JW, Horrow JC, Horne BD. Persistent increase in red cell size distribution width after acute diseases: a biomarker of hypoxemia? *Clin Chim Acta* 2015; 448: 107-117.
- Hu G, Wang S, Wang S, Huang L. Elevated baseline circulating platelet-to-lymphocyte ratio and survival in initial stage IV gastric cancer patients: a meta-analysis. *PLoS One* 2022; 17: e0265897.
- Yardan T, Meric M, Kati C, Celenk Y, Atici AG. Mean platelet volume and mean platelet volume/platelet count ratio in risk stratification of pulmonary embolism. *Medicina (Kaunas)* 2016; 52: 110-115.
- Lin W, Wu Y, Lu X, Hu Y. Association between mean platelet volume and pulmonary embolism: a systematic review and meta-analysis. *Aging (Albany NY)* 2021; 13: 17253-17273.